Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Shen, Hui ^a   Yamashita, Atsuya ^a   Nakakoshi, Masamichi ^b   Yokoe, Hiromasa ^c   Sudo, Masashi ^c   Kasai, Hirotake ^a   Tanaka, Tomohisa ^a   Fujimoto, Yuusuke ^a   Ikeda, Masanori ^d   Kato, Nobuyuki ^d   Sakamoto, Naoya ^e   Shindo, Hiroko ^a   Maekawa, Shinya ^a   Enomoto, Nobuyuki ^a   Tsubuki, Masayoshi ^c   Moriishi, Kohji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c HOSHI UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; CAFFEIC ACID; CAFFEIC ACID METHYL ESTER; CAFFEIC ACID N OCTYL ESTER; CAFFEIC ACID PHENETHYL ESTER; CHLOROGENIC ACID; CINNAMIC ACID HENETHYL ESTER; DACLATASVIR; DANOPREVIR; DIHYDROCAFFEIC ACID METHYL ESTER; FERULIC ACID; INTERFERON; LOMIBUVIR; ROSMARINIC ACID; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; INTRACELLULAR SIGNALING; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; REPLICON; STRUCTURE ACTIVITY RELATION; VIROGENESIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CAFFEIC ACIDS; HEPACIVIRUS; PHENYLETHYL ALCOHOL; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84893082812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082299     Document Type: Article

References (41)

1. Baldo V, Baldovin T, Trivello R, Floreani A (2008) Epidemiology of HCV infection. Curr Pharm Des 14: 1646-1654.
2. Moriishi K, Matsuura Y (2012) Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol 3: 54.
3. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 88: 5547-5551.
4. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, et al. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
5. Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8: 257-264.
6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
7. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1: S88-100.
8. Kieffer TL, Kwong AD, Picchio GR (2010) Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 65: 202-212.
9. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, et al. (2010) Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138: 1112-1122.
10. Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, et al. (2012) (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55: 720-729.
11. Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, et al. (2012) Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Int J Mol Med 30: 1021-1028.
12. Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, et al. (2012) Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat 19: e81-88.
13. Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, et al. (2009) Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem 284: 21165-21176.
14. Toyoda T, Tsukamoto T, Takasu S, Shi L, Hirano N, et al. (2009) Anti-inflammatory effects of caffeic acid phenethyl ester (CAPE), a nuclear factor-kappaB inhibitor, on Helicobacter pylori-induced gastritis in Mongolian gerbils. Int J Cancer 125: 1786-1795.
15. Ho CC, Lin SS, Chou MY, Chen FL, Hu CC, et al. (2005) Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo. J Antimicrob Chemother 56: 372-379.
16. Chiao C, Carothers AM, Grunberger D, Solomon G, Preston GA, et al. (1995) Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res 55: 3576-3583.
17. Boudreau LH, Maillet J, LeBlanc LM, Jean-Francois J, Touaibia M, et al. (2012) Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes. PLoS One 7: e31833.
18. Lee KW, Chun KS, Lee JS, Kang KS, Surh YJ, et al. (2004) Inhibition of cyclooxygenase-2 expression and restoration of gap junction intercellular communication in H-ras-transformed rat liver epithelial cells by caffeic acid phenethyl ester. Ann N Y Acad Sci 1030: 501-507.
19. Fesen MR, Kohn KW, Leteurtre F, Pommier Y (1993) Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A 90: 2399-2403.
20. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 93: 9090-9095.
21. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, et al. (2003) Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 163: 1167-1175.
22. Okamoto T, Omori H, Kaname Y, Abe T, Nishimura Y, et al. (2008) A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol 82: 3480-3489.
23. Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, et al. (2006) Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80: 4510-4520.
24. Lee Y, Shin DH, Kim JH, Hong S, Choi D, et al. (2010) Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol 643: 21-28.
25. Lee JC, Chen WC, Wu SF, Tseng CK, Chiou CY, et al. (2011) Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2. Antiviral Res 89: 35-42.
26. Lee JC, Tseng CK, Wu SF, Chang FR, Chiu CC, et al. (2011) San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression. J Viral Hepat 18: e315-324.
27. Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, et al. (2012) Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. Antimicrob Agents Chemother 56: 1315-1323.
28. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5: 453-463.
29. Lee YJ, Liao PH, Chen WK, Yang CY (2000) Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. Cancer Lett 153: 51-56.
30. Bourne GT, Golding SW, McGeary RP, Meutermans WD, Jones A, et al. (2001) The development and application of a novel safety-catch linker for BOC-based assembly of libraries of cyclic peptides. J Org Chem 66: 7706-7713.
31. Nagaoka T, Banskota AH, Tezuka Y, Saiki I, Kadota S (2002) Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. Bioorg Med Chem 10: 3351-3359.
32. Uwai K, Osanai Y, Imaizumi T, Kanno S, Takeshita M, et al. (2008) Inhibitory effect of the alkyl side chain of caffeic acid analogues on lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophages. Bioorg Med Chem 16: 7795-7803.
33. Zhang Z, Xiao B, Chen Q, Lian XY (2010) Synthesis and biological evaluation of caffeic acid 3,4-dihydroxyphenethyl ester. J Nat Prod 73: 252-254.
34. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, et al. (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4: 602-608.
35. Frese M, Barth K, Kaul A, Lohmann V, Schwarzle V, et al. (2003) Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. Journal of General Virology 84: 1253-1259.
36. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, et al. (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329: 1350-1359.
37. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, et al. (2010) Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol 45: 523-536.
38. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
39. Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, et al. (2012) Inhibition of hepatitis C virus replication and NS3 helicase by the extract of the feather star Alloeocomatella polycladia. Mar Drugs 10: 744-761.
40. Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, et al. (2012) Inhibition of Both Protease and Helicase Activities of Hepatitis C Virus NS3 by an Ethyl Acetate Extract of Marine Sponge Amphimedon sp. PLoS One 7: e48685.
41. Jin H, Yamashita A, Maekawa S, Yang PT, He LM, et al. (2008) Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication in vitro. Hepatology Research 38: 909-918.